Organ-on-a-Chip Resources

PhysioMimix® bioavailability assay kit: Human 18 for simultaneous oral and intravenous in vitro bioavailability profiling

Discover the PhysioMimix® Bioavailability assay kit: Human 18, the only in vitro tool for profiling human bioavailability. This Organ-on-a-chip solution bridges the gap between in vitro and in vivo studies, enhancing preclinical ADME testing for CROs, pharma, and biotech. Explore how it streamlines lead optimization and improves drug development accuracy.

Advancing oligonucleotide therapies with liver-on-a-chip models

Webinar Series 8 Episode 1

Discover how human-relevant models improve the understanding of drug delivery, efficacy, and safety of oligonucleotide therapies.

A liver microphysiological system to study the delivery and efficacy of oligonucleotide-based therapeutics

We introduce the PhysioMimix Liver MPS to study the delivery of oligonucleotides into the liver and their uptake by PHHs. The Liver MPS produces functional and stable PHH microtissues, enabling the study of gene knockdown and dosing strategies over 14 days.

Addressing the challenges of developing new modality drugs

Discover how new modality drugs are revolutionizing medicine by targeting complex diseases with cutting-edge therapies. Learn about the challenges, innovative solutions, and the role of AI and Organ-on-a-chip (OOC) technology in new modality drug development. Expert insights.

Multimodal imaging of a liver-on-a-chip model using labelled and label-free optical microscopy techniques

This recent multimodal imaging publication by Majer et al. (2024) from GSK explores the groundbreaking potential of 3D imaging of Liver-on-a-chip tissue to evaluate one of the biggest challenges in therapeutic ASOs: delivering oligonucleotides in sufficient concentration to the target tissue and cells of interest.

Validating a human dual-organ MPS for better drug (ADME) studies

In this video from Technology Networks’ Science Spotlight, Dr. Yassen Abbas, Lead scientist at CN Bio, discusses his research on ADME and how microphysiological system (MPS), also known as Organ-on-a-chip (OOC) technology can be used to evaluate the body’s effect on drugs.

The Rise of Oligonucleotide Therapeutics: Overcoming ADMET Development Challenges with Human-Centric Approaches

When developing oligonucleotide therapeutics, human-centric approaches are crucial for overcoming ADMET challenges and unlocking their full potential.

Find out through case studies how and why Organ-on-a-chip offers a path forward for the development of oligonucleotides targeting liver diseases by providing clearer insights into human-specific responses where in vivo models are less/unsuited.

A Gut/Liver microphysiological system for profiling human oral bioavailability

Webinar Series 7 Episode 4

Explore how the innovative Gut/Liver microphysiological system (MPS) enhances in vitro ADME profiling by linking primary human intestinal and liver cells to predict human drug bioavailability more accurately. This webinar demonstrates improved predictive capacity for complex drug behaviors, advancing drug discovery and safety assessment.

Evaluating Caco-2 cell’s gold-standard status in absorption, permeability and bioavailability Studies: Are Their Limitations Justified?

Caco-2 cells have long been heralded as the gold standard for studying intestinal absorption and permeability. However, as with any model system, Caco-2 cells have their own set of limitations. This raises important questions: Do their limitations undermine their gold-standard status? Is it time to improve estimations with more physiologically relevant approaches? What new approaches are available, and most importantly, do their benefits sufficiently outweigh the effort required to adopt a new approach?

6 Challenges in ADME Drug Development

Explore the current challenges in profiling preclinical human ADME through key publications. Can advances in the human relevance of preclinical models improve estimations for safer and more efficient drug development?

Liver-on-chip model and application in predictive genotoxicity and mutagenicity of drugs

Kopp et al., 2024. Current pre-clinical drug safety assessments lack a single, comprehensive test system for genotoxicity hazards identification. This study, aimed to develop an in vitro model to addresses this gap, looks at Organ-on-a-chip (OOC) technology as a solution. OOC present robust human metabolic activity and has the potential to assess all required endpoints for genotoxicity hazards identification, ultimately streamlining the process and eliminating the need for animal testing. This proof-of-concept experiment demonstrates the potential of PhysioMimix^® Liver-on-a-chip model as a promising tool for in vitro genotoxicity hazards identification, paving the way for a more streamlined and animal-free pre-clinical drug safety assessment process.

Defining validation criteria for a primary jejunum and primary hepatocyte dual-organ MPS

Improve in vitro to in vivo data translation for drug safety and efficacy with our fluidically-linked dual-organ MPS (microphysiological system); combining two well-characterized human Gut/Liver MPS – the RepliGut^® Jejunum and PhysioMimix® Liver MPS, in an interconnected model suitable for enhanced bioavailability profiling.